BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
9.90
-0.18 (-1.79%)
At close: Sep 5, 2025, 4:00 PM
10.23
+0.33 (3.33%)
After-hours: Sep 5, 2025, 7:59 PM EDT
Company Description
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients.
The company is based in South San Francisco, California. BridgeBio Oncology Therapeutics, Inc. operates as a subsidiary of BridgeBio Pharma, Inc.
BridgeBio Oncology Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Eli Wallace |
Contact Details
Address: 256 E. Grand Avenue, Suite 104 South San Francisco, California 94080 United States | |
| Phone | 650 405 4770 |
| Website | bbotx.com |
Stock Details
| Ticker Symbol | BBOT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US1079241022 |
Key Executives
| Name | Position |
|---|---|
| Eli M. Wallace Ph.D. | Chief Executive Officer and Director |
| Dr. Pedro J. Beltran M.D., Ph.D. | Chief Scientific Officer |
| Dr. Yong Ben M.B.A., M.D. | Chief Medical and Development Officer |
| Uneek Mehra M.B.A. | Chief Financial Officer |
| Howard Y. Chang M.D., Ph.D. | Vice President of Operations |
| Aaron Chan J.D. | Vice President of Legal |
| Angela Peters | Senior Vice President of People |
| Idan Elmelech M.A., M.B.A. | Senior Vice President of Strategy and Business Development |
| Bin Wang Ph.D. | Senior Vice President of Drug Discovery |
| Keshi Wang Ph.D. | Senior Vice President of DMPK and Clinical Pharmacology |